Home | Contact Us

Press room

Articles

Diagnostic Tools for Testicular Tumors ADVANCE, July 2009: Vol. 18 No. 7

Genetic Tests May Reveal Source of Mystery Tumors New York Times, March 2009

Press releases

Mar 2012 New Studies Demonstrate Clinical Utility and Validity of CancerTYPE ID® Molecular Classifier
Jan 2012 bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
Dec 2011 bioTheranostics Breast Cancer IndexSM shows clinical utility in late recurrence prognosis and identification of patients eligible for breast conserving surgery
Nov 2011 bioTheranostics CancerTYPE ID® Linked with Improved Clinical Outcome and Longer Survival
July 2011 New Study Reports: CancerTYPE ID® Expands Tumor Type Coverage and Demonstrates Clinical Utility
June 2011 Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer IndexSM Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
Dec 2010 bioTheranostics Breast Cancer IndexSM predicts risk for late recurrence in early stage ER-positive breast cancer patients

 

Archived Press Releases

 

For information about bioTheranostics or to speak with a company representative, please contact:

Tim Schofield

bioTheranostics

(858) 587-5890 office

tim.schofield@biotheranostics.com

About
© 2012 bioTheranostics. All rights reserved.
+1 (877) 886-6739 client services
Privacy Policy  |  Site Map  |  Speaker Bureau |  webmail